Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

DOI Web Site 被引用文献1件
  • Benjamin L. Sievers
    J. Craig Venter Institute, La Jolla, CA 92037, USA.
  • Saborni Chakraborty
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Yong Xue
    J. Craig Venter Institute, Rockville, MD 20850, USA.
  • Terri Gelbart
    J. Craig Venter Institute, La Jolla, CA 92037, USA.
  • Joseph C. Gonzalez
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Arianna G. Cassidy
    Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94115, USA.
  • Yarden Golan
    Department of Bioengineering and Therapeutic Sciences, and Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94115, USA.
  • Mary Prahl
    Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94115, USA.
  • Stephanie L. Gaw
    Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94115, USA.
  • Prabhu S. Arunachalam
    Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Catherine A. Blish
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Scott D. Boyd
    Departments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Mark M. Davis
    Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Prasanna Jagannathan
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Kari C. Nadeau
    Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA 94305, USA.
  • Bali Pulendran
    Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Upinder Singh
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Richard H. Scheuermann
    J. Craig Venter Institute, La Jolla, CA 92037, USA.
  • Matthew B. Frieman
    Department of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Sanjay Vashee
    J. Craig Venter Institute, Rockville, MD 20850, USA.
  • Taia T. Wang
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Gene S. Tan
    J. Craig Venter Institute, La Jolla, CA 92037, USA.

説明

<jats:p>Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by preexisting immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wild-type (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses, whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ